- Home
- CYCN vs GLMD Comparison
CYCN vs GLMD Comparison
Compare CYCN & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- GLMD
- Stock Information
- Founded
- CYCN 2018
- GLMD 2000
- Country
- CYCN United States
- GLMD Israel
- Employees
- CYCN N/A
- GLMD N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- GLMD Health Care
- Exchange
- CYCN Nasdaq
- GLMD Nasdaq
- Market Cap
- CYCN 7.6M
- GLMD 8.0M
- IPO Year
- CYCN N/A
- GLMD 2014
- Fundamental
- Price
- CYCN $2.25
- GLMD $1.41
- Analyst Decision
- CYCN
- GLMD Hold
- Analyst Count
- CYCN 0
- GLMD 1
- Target Price
- CYCN N/A
- GLMD N/A
- AVG Volume (30 Days)
- CYCN 1.1M
- GLMD 72.8K
- Earning Date
- CYCN 11-13-2025
- GLMD 11-13-2025
- Dividend Yield
- CYCN N/A
- GLMD N/A
- EPS Growth
- CYCN N/A
- GLMD N/A
- EPS
- CYCN N/A
- GLMD N/A
- Revenue
- CYCN $2,174,000.00
- GLMD N/A
- Revenue This Year
- CYCN N/A
- GLMD N/A
- Revenue Next Year
- CYCN N/A
- GLMD N/A
- P/E Ratio
- CYCN N/A
- GLMD N/A
- Revenue Growth
- CYCN N/A
- GLMD N/A
- 52 Week Low
- CYCN $1.27
- GLMD $1.15
- 52 Week High
- CYCN $9.47
- GLMD $4.81
- Technical
- Relative Strength Index (RSI)
- CYCN 42.18
- GLMD 43.70
- Support Level
- CYCN $2.23
- GLMD $1.37
- Resistance Level
- CYCN $2.46
- GLMD $1.50
- Average True Range (ATR)
- CYCN 0.18
- GLMD 0.10
- MACD
- CYCN -0.03
- GLMD -0.02
- Stochastic Oscillator
- CYCN 19.05
- GLMD 16.67
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.